News

Jun 01 2018

Auris Health made the coveted CNBC Disruptor 50 List for 2018, making it one of the few healthcare companies to receive the honor. Each year CNBC features private companies of all types whose game-changing innovations are transforming how the world does business. Joining the ranks of Airbnb, Lyft, and SpaceX, Auris was honored for the innovative work it brings to bronchoscopic procedures with its Monarch Platform. The goal of Auris’s robotic technology is to enable more accurate diagnosis, and eventually treatment, of small and hard-to-reach nodules in the periphery of the lung.

May 15 2018

Auris announced its collaboration with NeuWave Medical, a subsidiary of Ethicon, Inc. and part of the Johnson & Johnson Medical Devices Companies this week. The goal is to enable robotically assisted bronchoscopic ablation of lesions in the lung. This cooperative development and commercialization agreement calls for a co-development of integrated systems for robotic control, navigation and application of microwave ablation delivered via bronchoscopes.

Apr 12 2018

Dr. Frederic Moll, CEO of Auris Health was featured in The Wall Street Journal in an article about Auris and its innovative technologies. Dr. Moll, a serial entrepreneur and surgical robotics visionary, helped pioneer Auris’s beginnings and has pushed for medical innovation for over 30 years. He co-founded his first start-up, Endotherapeutics Corp., in the 1980s, developing products for laparoscopic or minimally invasive surgery. Gil Kliman, an investor in Restoration Robotics (another one of Dr. Moll’s ventures), said of Dr. Moll’s drive for success: “He is the one human that will never be replaced by a robot. He won’t give up on things; he can push though the inevitable naysayers.”

Apr 03 2018

Since Auris has received FDA clearance for its Monarch Platform, the innovative robotic technology is catching the attention of many in the healthcare and robotics space. The Monarch Platform was featured in an article by Surgical Products Magazine. According to the article, the Monarch Platform’s approach to flexible technology with its application in bronchoscopy could be a game-changer. The article explains why Auris Health CEO, Dr. Frederic Moll, believes the technology has the potential to transform the treatment of lung cancer. It also explains how Dr. Moll’s guidance has shaped the direction of Auris, including the acquisition of Hansen Medical’s technology.

Mar 29 2018

Auris’s Monarch Platform was featured in MedGadget, an online publication that covers the latest news in medical technology around the world, in an article titled “Monarch Robotic Endoscopy for Spotting Small, Deep-Seated Lung Nodules Cleared by FDA.”

Mar 25 2018

Auris is featured in this TechCrunch article, titled “Monarch is a new platform from surgical robot pioneer Frederic Moll,” for the reveal of its robotic endoscopic technology called the Monarch Platform. With the use of the Monarch Platform’s flexible robotics and controller, a physician can navigate to hard-to-reach places in the periphery of the lung. Auris’s goal is to help clinicians diagnose and treat lung cancer in the early stages, because the prognosis for lung cancer is worse for the patient if it is discovered at an advanced stage.

Mar 23 2018

Fred Moll’s Auris Health has been granted FDA clearance for its surgical robotics platform. The nod clears the Intuitive Surgical founder’s latest venture to sell the device for use in bronchoscopic diagnostic and therapeutic procedures in lung cancer patients.

Mar 23 2018

Operated by a hand-held controller, Auris Health’s recently FDA-cleared Monarch Platform has lung cancer as its first targeted disease state. According to the article, the FDA determined the technology Auris built was equivalent to other bronchoscopic procedures that use endoscopy to examine a patient’s lungs. However, with the integration of the latest advancements in robotics, software, data science, and endoscope innovation, Auris aims to go further than conventional endoscopy.

Mar 23 2018

Auris Health's Monarch Platform has been cleared by the FDA. The company's Chief Strategy Officer, Josh DeFonzo, summarizes some of the key features and benefits of the new technology, aimed to improve the current bronchoscopy procedure.

Jan 19 2018

Auris Health, formerly known as Auris Surgical Robotics, made its way to the top for most venture capital funding in the medical device industry in 2017, marking an exciting time not only for Auris but for the industry overall last year.